Germany has recommended the AstraZeneca coronavirus vaccine should only be given to people under the age of 65, according to reports.
The country’s vaccine committee has reportedly said the jab, developed alongside the University of Oxford, should only be offered to people aged between 18 and 64.
It gave a lack of sufficient data on the effectiveness of the inoculation in older people as the reason for the decision in a draft recommendation.
- December 9 – UK authorities confirmed 2 cases of anaphylaxis after vaccination
- December 18*, 2020 – CDC has identified 6 case reports of anaphylaxis following Pfizer-BioNTech vaccine meeting Brighton Collaboration criteria for anaphylaxis
- Persons with anaphylaxis following COVID-19 vaccination should not receive additional doses of COVID-19 vaccine
A hospital worker with no history of allergies was admitted to intensive care over a severe reaction she suffered 10 minutes after having Pfizer’s coronavirus vaccine. The unidentified female worker suffered an anaphylactic reaction shortly after receiving the injection at a hospital in Juneau, Alaska, on Tuesday.
Two healthcare workers in the UK suffered an anaphylactic reaction to the Pfizer injection after being given it last week, although the vaccine has been widely tested and analysed, with government experts in both the US and Great Britain deeming it safe.
More than 100,000 patients will not be able to get the Covid vaccine from their family doctor after their GP surgeries decided not to take part in its deployment, the Guardian can reveal.
The UK government has granted pharmaceutical giant Pfizer a legal indemnity protecting it from being sued, enabling its coronavirus vaccine to be rolled out across the country as early as next week.
The Department of Health and Social Care has confirmed the company has been given an indemnity protecting it from legal action as a result of any problems with the vaccine.
Ministers have also changed the law in recent weeks to give new protections to companies such as Pfizer, giving them immunity from being sued by patients in the event of any complications.
NHS staff providing the vaccine, as well as manufacturers of the drug, are also protected.
Most people will escape “severe” side effects, defined as those that prevent daily activity. Fewer than 2% of recipients of the Pfizer and Moderna vaccines developed severe fevers of 39°C to 40°C. But if the companies win regulatory approvals, they’re aiming to supply vaccine to 35 million people worldwide by the end of December. If 2% experienced severe fever, that would be 700,000 people.
Other transient side effects would likely affect even more people. The independent board that conducted the interim analysis of Moderna’s huge trial found that severe side effects included fatigue in 9.7% of participants, muscle pain in 8.9%, joint pain in 5.2%, and headache in 4.5%. In the Pfizer/BioNTech vaccine trial, the numbers were lower: Severe side effects included fatigue (3.8%) and headache (2%).
But that’s a higher rate of severe reactions than people may be accustomed to. “This is higher reactogenicity than is ordinarily seen with most flu vaccines, even the high-dose ones,” says Arnold Monto, an epidemiologist at the University of Michigan School of Public Health.
- Vaccine produced by a partnership between a University of Oxford research institute, Vaccitech, and AstraZeneca, does not need to be stored at freezing temperatures.
- Cheaper and easier to produce than the high-efficacy vaccines produced by BioNTech-Pfizer and Moderna.
- The price of AstraZeneca’s shares dropped on the news, and an analysis from an investment bank concluded, “We believe that this product will never be licensed in the US.”
- A closer look at the the Oxford-AstraZeneca trials reveals some very shaky science.
- Cherry-picked the data
- Dosing issues
- Opaque planning and data analysis procedures
- Age group selection